SAN CARLOS, Calif., April 25, 2024 /PRNewswire/ -- RevOpsis Therapeutics, a next-generation biopharmaceutical company spearheading innovation in ophthalmic therapies, announced today it has successfully closed its first seed funding round, raising $16.5 million to propel its mission to develop and commercialize treatments for chronic multifactorial diseases through the company's fully human multispecific proprietary Rev-Mod Platform.
Shockwave Medical Completes Acquisition of Neovasc
Neovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update
Neovasc Shareholders Approve Acquisition by Shockwave Medical
Neovasc Announces German Reimbursement Renewal
Shockwave Medical to Acquire Neovasc
Shockwave Medical Announces Agreement to Acquire Neovasc
In a deal that might as well be termed a heart-to-heart, Shockwave Medical has made a bid to combine Neovasc’s cardiac device business with its own.
VANCOUVER and MINNEAPOLIS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced an update on the COSIRA-II Clinical...
VANCOUVER and MINNEAPOLIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the third quarter ended September 30, 2022.